share_log

和黃醫藥:自願性公告-和黃醫藥將於即將舉行的2022年ESMO年會上公佈Fruquintinib治療難治性的轉移性結直腸癌的FRESCO-2國際多中心III期研究數據總結

HUTCHMED: VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation

Sep 7, 2022 18:30
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more